Tag : NIVOLUMAB

In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.

In advanced HCC, the tumor microenvironment fosters immune evasion by upregulating inhibitory pathways that suppress cytotoxic T-cell activity. Nivolumab + ipilimumab enhance antitumor immune responses by blocking these inhibitory signals and restoring T-cell function. Nivolumab + ipilimumab has demonstrated superior overall survival (OS) and durable responses compared to sorafenib in untreated advanced HCC.3 Based on these findings, the dual immunotherapy has been approved by the FDA as a first-line treatment for patients with unresectable or metastatic HCC without prior systemic therapy, offering a promising alternative to kinase inhibitor-based therapies.

With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab + ipilimumab as a first-line therapy for untreated aRCC.